Overview

Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Status:
Completed

Trial end date:
2016-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate progression-free survival among subjects with KRAS mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib (ARQ 197) compared to single agent chemotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

ArQule
ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)

Treatments:

Docetaxel
Erlotinib Hydrochloride
Gemcitabine
Pemetrexed